MyndLink: AI-Powered Intelligence for Transforming Neurological Treatment

MyndLink™ is an AI-powered therapy assistant currently under development, fueled by agentic reasoning listening frameworks, designed to maximize neurological treatment outcomes by providing real-time, data-driven recommendations with predictive analytics.

MyndLink is currently in development and is not yet available for clinical use. The capabilities described on this page represent intended design goals and are subject to change. MyndLink’s safety and effectiveness have not been established or approved by any regulatory authority. See additional details below.”

MyndLink is being developed to help healthcare providers optimize treatment protocols for stroke and spinal cord injury rehabilitation, addressing the 60-70% of stroke survivors who experience persistent upper limb impairment1. 2. 3.. The platform is designed to automate clinical documentation by capturing therapy sessions in real-time, eliminating manual note-taking and generating comprehensive treatment records automatically. This is intended to allow therapists to focus on patient care rather than paperwork while providing objective outcome data required for value-based care and insurance authorizations. The same intelligent automation and predictive analytics optimize treatment protocols for spinal cord injury patients, documenting progress to support recovery and justify continued therapy.

Beyond rehabilitation, MyndTec is exploring a solution to chronic pain’s multi-billion-dollar problem6,10. The MyndLink system is also being explored to optimize Spinal Cord Stimulation (SCS) patient selection and reduce the 25-30% failure rate5. through AI-powered predictive analysis, with the goal of helping providers predict which patients will truly benefit from spinal cord stimulation therapy— potentially reducing the trial-and-error approach that causes 25-30% of procedures to fail5..

By predicting which treatments and patients will benefit most, MyndLink aims to improve clinical outcomes and lower healthcare costs by minimizing unsuccessful procedures. The urgency is clear — stroke-related costs in the United States reached nearly $56.2 billion between 2019 and 2020 alone4, encompassing health care services, medications, and lost productivity. As stroke and spinal cord injury rehabilitation costs continue to escalate, MyndLink’s ability to optimize treatment selection and automate clinical documentation directly reduces waste and accelerates the path to recovery — delivering measurable value to providers, payers, and patients alike.

Market Facts

Stroke & Spinal Cord Injury (SCI) Rehabilitation: The North American Neurorehabilitation market leads all global regions with the highest growth rate, at a CAGR of 8.3% through 2030, within a global market projected to reach USD 2.45 billion by 20307. The market is driven by 795,000 annual stroke cases in US4 and 18,000 new spinal cord injury cases8 annually, distributed among approximately 1,250 Inpatient Rehabilitation Facilities and 17,000 Outpatient Neuro/Rehab Clinics9.

Chronic Pain / Spinal Cord Stimulation (SCS): The global SCS market, valued at USD 3.52 billion in 2025, is projected to grow to USD 6.48 billion by 2032 at a CAGR of 9.1%10., driven by rising chronic pain prevalence, aging populations, and demand for minimally invasive treatments. North America dominates with 74.44% of global market share in 202510, distributed among hospitals, ambulatory surgery centers, and specialty clinics9. Reinforcing this urgency, CMS identified chronic pain procedures as costing Medicare nearly $6 billion in low-value treatments in 2022 alone6, prompting the launch of an AI-driven prior authorization review program in 2026 — underscoring the critical need for smarter patient selection tools like MyndLink.

How It Is Designed to Work:

  • MyndLink will analyze each patient’s unique medical profile and treatment history
  • AI algorithms will determine the most effective treatment path and predict outcomes
  • Healthcare providers will receive clear insights, enabling personalized care tailored to each patient’s needs.

A Vision for Revolutionizing Neurological Treatment:

  • Stroke & SCI Rehabilitation: MyndLink is being designed to predict optimal treatment protocols, automate clinical documentation, and provide objective outcome data for value-based care.
  • Chronic Pain Treatment: Aiming to end the guesswork in Spinal Cord Stimulation (SCS). MyndLink is being designed to predict which patients will respond positively.

Note: MyndLink is currently in development and is not yet available for clinical use; its safety and effectiveness have not yet been established. Primary development focus: Stroke and spinal cord injury rehabilitation (2026-2028). Chronic pain applications represent early-stage research exploration.

  1. PMC Rehabilitation Study (2022) – https://pmc.ncbi.nlm.nih.gov/articles/PMC8872602/
  2. Vivistim Upper Limb Impairment Review (2022) – https://www.vivistim.com/life-after-stroke-3-facts-you-should-know-about-upper-limb-impairment/
  3. ACNR Journal (2019) – https://acnr.co.uk/articles/an-expert-opinion-upper-limb-rehabilitation-after-stroke/
  4. CDC Stroke Facts 2024 – https://www.cdc.gov/stroke/data-research/facts-stats/index.html
  5. Dougherty, M. C., et al. (2021). Risk Factors and Survival Analysis of Spinal Cord Stimulator Explantation. Neuromodulation, 24(1), 61–67 – https://doi.org/10.1111/ner.13173
  6. Anson, P. (September 16, 2025). Medicare Pilot Program Will Use AI To Decide If Pain Treatments Are Worth the Cost. Pain News Network. [CMS WISeR Model — chronic pain procedures cost Medicare nearly $6 billion in low-value treatments in 2022]
  7. Allied Market Research (2021). Neurorehabilitation Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021–2030 – https://www.alliedmarketresearch.com/press-release/neurorehabilitation-market.html
  8. National Spinal Cord Injury Statistical Center, 2024 SCI Facts and Figures – https://sites.uab.edu/nscisc/
  9. CMS Provider Data; Newsweek/Statista Physical Rehabilitation Centers Rankings 2024 – https://rankings.newsweek.com/americas-best-physical-rehabilitation-centers-2024
  10. Fortune Business Insights (2025). Spinal Cord Stimulation Market Size, Share and Regional Forecast 2020–2032. [Global SCS market valued at USD 3.52B in 2025; projected USD 6.48B by 2032; CAGR 9.1%; North America 74.44% market share in 2025]